Supreme Court Temporarily Restores Mail-Order Access to Abortion Pill

The U.S. Supreme Court has temporarily restored access to the abortion pill mifepristone via mail order, telehealth, and pharmacies, following a temporary stay issued by Justice Samuel A. Alito on May 4, 2026. This decision comes in response to a previous ruling by the U.S. Court of Appeals for the Fifth Circuit that restricted such access ^[1][2].

On May 1, 2026, the Fifth Circuit had ruled to block mail-order and telehealth access to mifepristone, requiring in-person dispensing only. This ruling was the result of a lawsuit brought by the state of Louisiana against the U.S. Food and Drug Administration (FDA) ^[1][2].

In response to the Fifth Circuit’s decision, two drugmakers, Danco Laboratories and GenBioPro, filed emergency applications with the Supreme Court on May 2, 2026, seeking to restore mail-order access to the drug ^[2][3].

Justice Alito’s temporary stay, effective for at least one week, allows the continued distribution of mifepristone through telehealth and mail, as had been permitted under FDA rules since 2023 ^[1][4]. This stay temporarily reverses the Fifth Circuit’s ruling, which had significantly curtailed access to the drug nationwide, particularly affecting states with abortion bans ^[1][2].

What Is Known:

• The Supreme Court’s temporary stay restores the ability to obtain mifepristone through mail order and telehealth services ^[1][4].
• The Fifth Circuit’s ruling had previously limited access, requiring in-person dispensing of the drug ^[1][2].
• The temporary stay is in place for at least one week while the Supreme Court considers the matter further ^[1][4].

What Remains Unclear:

• The long-term status of mail-order access to mifepristone remains uncertain as the Supreme Court continues to deliberate ^[1][4].
• The potential impact of the Supreme Court’s final decision on states with existing abortion bans is yet to be determined ^[1][2].